Comparison of two novel agents in slowing the progression of chronic kidney disease in patients with type 2 diabetes by Kaye, Emily
Emily Kaye, MMS (c), MPH (c)
Faculty Advisor:  Amanda Seymour, MS, PA-C
Department of Medical Science
• Chronic kidney disease (CKD) is a progressive disease 
process leading to kidney function decline and failure 
• One of the leading causes of CKD is type 2 diabetes1
• 9.4% of the U.S. population (30.3 million people) have 
diabetes with type 2 accounting for 90-95% of cases2
• Approximately 35-40% of patients with type 2 diabetes have 
some degree of kidney disease3,4
• Novel agents have been developed to help manage patients 
with type 2 diabetes with hopes of renoprotective benefits
• These agents include sodium-glucose cotransporter-2 
inhibitors (SGLT-2) and glucagon-like peptide-1 (GLP-1) 
receptor agonists 
Introduction Table 1. Comparison of Results
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Comparison of two novel agents in slowing the progression of chronic kidney disease 
in patients with type 2 diabetes
Chronic kidney disease (CKD) is a progressive disease process 
that leads to a decline in kidney function and eventual kidney 
failure. One of the leading causes of CKD is type 2 diabetes. 
Novel diabetic agents have been developed and have shown 
promise in slowing the progression of CKD in patients with type 
2 diabetes. The purpose of this review was to compare SGLT-2 
inhibitors (I) and GLP-1 receptor agonists (C) to determine their 
impact on nephropathy indicators (O) in type 2 diabetic patients 
with CKD (P). 
Abstract
• A literature search was conducted in November 2018 
• Pub Med:
• (nephropathy[Title/Abstract]) AND sglt2 
inhibitor[Title/Abstract]
• “nephropathy AND glp-1 receptor agonist”
• Human studies published in the last 10 years 
written in English
• Biomedical Sciences Reference Collection:
• “nephropathy (as a subject term) AND sglt2 
inhibitors NOT mice or rats or rodents”
• “nephropathy (as a subject term) AND glp1 
receptor agonists NOT mice or rats or rodents”
• Written in English since 2013, scholarly peer 
reviewed journals, and full texts 
• Inclusion of at least one marker of nephropathy: proteinuria, 
creatinine clearance, estimated glomerular filtration rate
• 8 articles were critically appraised and compared
Methods
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• Imamura et al and Dicembrini et al showed risk reduction of developing 
nephropathy, slower decline in eGFR, and decrease in proteinuria in 
patients receiving GLP-1 receptor agonists
• Four of 6 studies on SGLT-2 inhibitors found that patients treated with 
SGLT-2 inhibitors either experienced an increase, no change, or slower 
decrease in eGFR compared to the control group
• Heerspink et al and Kohan et al showed that eGFR initially declined in 
patients taking SLGT-2 inhibitors but stabilized by 2 years to a rate 
slower than that of the comparison group
• Wanner et al showed a 39% decrease in risk of development of 
nephropathy in the group treated with the SGLT-2 inhibitor empagliflozin
Results
Key: S = significant based on p value (p<0.01); NS = not significant (no p value or p value not significant)
eGFR Serum Creatinine BUN
Urine 
Albumin:Creatinine
Ratio
Creatinine Clearance
G = increase, no change, 
or slower decrease in 
eGFR in treatment 
group relative to control
G = decrease, no 
change, or slower 
increase in serum 
creatinine in treatment 
group relative to control
G = decrease, no 
change, or slower 
increase in BUN in 
treatment group relative 
to control
G = decrease, no 
change, or slower 
increase in ACR in 
treatment group relative 
to control
G = increase, no change, 
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treatment group relative 
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B = larger decrease in 
eGFR after treatment 
relative to control
B = larger increase in 
serum creatinine after 
treatment relative to 
control 
B = larger increase in 
BUN after treatment 
relative to control
B = larger increase in 
ACR after treatment 
relative to control 
B = larger decrease after 
treatment relative to 
control
Traditionally, patients with type 2 diabetes are treated with metformin, 
insulin, as well as ACEIs or ARBs, to provide glycemic control and 
renoprotection. However, once patients have progressed to CKD, this 
treatment regimen is not as successful at slowing this process. 
Slowing the progression of CKD can delay the decline in eGFR and 
the need to start dialysis in this patient population. The data gathered 
in this review suggests that, in the long term, SLGT-2 inhibitors might 
be beneficial for stabilizing eGFR and preventing rapid decline. Data 
from the multiple studies that lasted at least 2 years showed that, 
initially, patients treated with SGLT-2 inhibitors experience a brief sharp 
decline in eGFR, which then trends back towards baseline and 
stabilizes over time. One of the explanations offered was that the initial 
volume depletion associated with SGLT-2 inhibitors created a dose-
dependent effect that initially shows a decrease in eGFR and increase 
in other renal markers such as BUN and serum creatinine. Additionally, 
there exists research indicating SGLT-2 inhibitors have other beneficial 
impacts on health outcomes, such as improving glycemic control, 
lowering systolic blood pressure, and reducing body weight. The two 
studies evaluating GLP-1 agonists suggest they might have a role in 
decreasing proteinuria, rate of eGFR decline, and risk of nephropathy. 
Discussion
There is limited generalizability of the results of the SGLT-2 clinical 
trials, as the majority required patients to have an eGFR of at least 30 
mL/min/1.73m2 and there was limited racial diversity among the 
samples. The initial data from these clinical trials are promising, and 
further studies should be conducted that increase length of treatment 
and diversify the treatment group. There exists no direct comparison 
between SGLT-2 inhibitors and GLP-1 receptor agonists, so a 
definitive comparison cannot be made. As there exists limited 
treatment options that can assist in slowing the progression of CKD, 
SGLT-2 inhibitors should be seriously considered given the preliminary 
renoprotective effects they exhibit, limited relative safety concerns, and 
evidence for improved glycemic control, systolic blood pressure, and 
body weight. 
Conclusion
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